Drug Trial Radar · NCT01749878
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Last checked: Nov 20, 2026Latest source record: May 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Dec 2012
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Dec 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind study of the safety, tolerability, and bioeffect of REGN1500
Conditions
- Hypertriglyceridemia
Interventions
REGN1500Drug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: Day 1 to Day 106/126
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Philadelphia, Pennsylvania
Site not named
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.